Savara Inc. Aktie
Deine Einschätzung
Savara Inc. Aktie
Was spricht für und gegen Savara Inc. in den nächsten Jahren?
Pro
Kontra
Rendite von Savara Inc. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
Savara Inc. | -1,22 % | - | - | - | - | - | - |
Rockwell Medical Inc. | 3,25 % | 4,36 % | 20,16 % | -23,56 % | -4,79 % | -79,21 % | -96,62 % |
Avid Bioservices Inc | -1,20 % | 0,00 % | 38,66 % | -38,89 % | 35,25 % | -49,70 % | 161,16 % |
Gritstone Oncology Inc | -1,88 % | 8,75 % | 10,80 % | -57,95 % | -58,85 % | -89,74 % | - |
Kommentare
News
Savara Presented New Data on Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society (ATS) International Conference 2024
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a poster at the American Thoracic Society (ATS) 2024
Savara Announces New Employment Inducement Grant
Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On May 14, 2024
Savara Reports First Quarter 2024 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2024 and